{"schema_version":"secwatch.filing_event.v1","accession":"0001178913-26-003796","form_type":"8-K","ticker":"SLXN","cik":"0002022416","company_name":"Silexion Therapeutics Corp","filed_at":"2026-08-04T20:10:48+00:00","discovered_at":"2026-08-04T20:12:00.309564+00:00","generated_at":"2026-08-04T20:12:20.194844+00:00","sec_items":["7.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Silexion: SIL204 shows multi-mechanism immune sensitization in KRAS-driven cancers","bullets":["SIL204 treatment produced statistically significant upregulation of FAS (death receptor) and downregulation of HLA-G (immune checkpoint) in human KRAS-mutant pancreatic and NSCLC cell lines.","Combined with prior MHC-I upregulation, data supports coordinated immune-sensitization across three key immune pathways.","Findings observed across four distinct KRAS mutations (G12D, G12V, G12C, G12R) in pancreatic and NSCLC models.","Company advancing SIL204 into Phase 2/3; first clinical trial site initiated at Tel Aviv Sourasky Medical Center in July 2026.","Management believes data supports combining SIL204 with anti-PD-(L)1 checkpoint inhibitors."],"urls":{"canonical":"https://secwatch.observer/filing/0001178913-26-003796","json":"https://secwatch.observer/filing/0001178913-26-003796.json","markdown":"https://secwatch.observer/filing/0001178913-26-003796.md","text":"https://secwatch.observer/filing/0001178913-26-003796.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/2022416/000117891326003796/0001178913-26-003796-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/2022416/000117891326003796/zk2635818.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-08-04T20:12:20.194844+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}